As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Amneal Pharmaceuticals, Inc. The largest reported stake is Tushar Patel's, at 17.6%. 9 filings are on record since August 8, 2025 (Schedule 13D/A, August 12, 2026).
Sell to companies like Amneal Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Tushar Patel · Sole voting: 61,341,678 · Shared voting: 0 · Sole dispositive: 61,341,678 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-12
- · Reporting person: Chintu Patel · Sole voting: 32,576,528 · Shared voting: 0 · Sole dispositive: 32,576,528 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-12
- · Reporting person: Chirag Patel · Sole voting: 29,097,645 · Shared voting: 0 · Sole dispositive: 29,097,645 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-12
- · Holder: BlackRock, Inc. · Percent: 7.6% · SCHEDULE 13G
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Amneal Pharmaceuticals, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-08. 5 holders' latest filing reports 5% or more of class a common stock, par value $0.01. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 17.6% | 61,341,678 | SCHEDULE 13D/A, 2026-08-12 | 2026-08-10 | |
| 9.4% | 32,576,528 | SCHEDULE 13D/A, 2026-08-12 | 2026-08-10 | |
| 8.4% | 29,097,645 | SCHEDULE 13D/A, 2026-08-12 | 2026-08-10 | |
| BlackRock, Inc. | 7.6% | 24,121,119 | SCHEDULE 13G, 2026-04-27 | 2026-03-31 |
| 5.4% | 16,904,263 | SCHEDULE 13D/A, 2026-03-26 | 2025-12-31 | |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Amneal Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Amneal Pharmaceuticals, Inc. and the records around it.
Amneal Pharmaceuticals, Inc. elsewhere on the record
Companies that share a holder
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Amneal Pharmaceuticals, Inc.
Get an email when Amneal Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Amneal Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Amneal Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Amneal Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Tushar Patel | 61,341,678 | 0 | 61,341,678 | 0 | SCHEDULE 13D/A, 2026-08-12 |
| Chintu Patel | 32,576,528 | 0 | 32,576,528 | 0 | SCHEDULE 13D/A, 2026-08-12 |
| Chirag Patel | 29,097,645 | 0 | 29,097,645 | 0 | SCHEDULE 13D/A, 2026-08-12 |
The latest filing identifies Amneal Pharmaceuticals, Inc. by CUSIP 03168L105 and gives its principal executive office as 400 CROSSING BOULEVARD, 3RD FLOOR, BRIDGEWATER, NJ 08807 (SCHEDULE 13D/A, 2026-08-12).
Source of funds (Item 3)
The disclosure in Item 3 is hereby amended and supplemented by adding the following: On April 21, 2026, Rock Nola, LLC, a Delaware limited liability company ("Rock Nola") the sole member of which is a trust controlled by the Reporting Person, entered into a Membership Interest Purchase Agreement (the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC (the "Seller Representative") and the equityholders of Kashiv named therein, including Rock Nola (the "Sellers").Tushar Patel, SCHEDULE 13D/A, 2026-08-12
Purpose of Transaction (Item 4)
Chirag Patel
This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 7, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-12
Patel Dipan
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42.Item 4 of the SCHEDULE 13D/A filed 2026-03-26
Chintu Patel
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-12
Tushar Patel
This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 6, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 6 shall have the meanings set forth in the Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-12
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-08 | Patel Chirag K. | 7.1% | SCHEDULE 13D/A |
| 2025-10-06 | Patel Dipan | 7.6% | SCHEDULE 13D/A |
| 2025-10-07 | Patel Chintu | 8.2% | SCHEDULE 13D/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-03-26 | Patel Dipan | 5.4% | SCHEDULE 13D/A |
| 2026-04-27 | BlackRock, Inc. | 7.6% | SCHEDULE 13G |
| 2026-08-12 | Chintu Patel | 9.4% | SCHEDULE 13D/A |
| 2026-08-12 | Chirag Patel | 8.4% | SCHEDULE 13D/A |
| 2026-08-12 | Tushar Patel | 17.6% | SCHEDULE 13D/A |
Questions about who owns Amneal Pharmaceuticals, Inc.
Who owns Amneal Pharmaceuticals, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Amneal Pharmaceuticals, Inc.: Tushar Patel (17.6%, Schedule 13D/A, filed 2026-08-12), Chintu Patel (9.4%, Schedule 13D/A, filed 2026-08-12), Chirag Patel (8.4%, Schedule 13D/A, filed 2026-08-12), BlackRock, Inc. (7.6%, Schedule 13G, filed 2026-04-27) and Patel Dipan (5.4%, Schedule 13D/A, filed 2026-03-26).
Who are the largest shareholders of Amneal Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Amneal Pharmaceuticals, Inc. on this page are Tushar Patel (17.6%), Chintu Patel (9.4%) and Chirag Patel (8.4%).
When did Tushar Patel buy into Amneal Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tushar Patel on this page is the Schedule 13D/A, filed 2026-08-12, reporting 17.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Amneal Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.